Overexpression of NPRL2 in colon cancer cells increased the sensitivity to a topoisomerase I inhibitor, irinotecan (CPT-11), by activating the DNA damage checkpoints [89]. This evidence concerns the gene NPRL2 and malignant colon neoplasm.